utidelone

Utidelone is a novel small molecule antineoplastic agent of the epothilone class. It is a genetically engineered analog of epothilones produced by manipulation of the biosynthetic gene cluster in Sorangium cellulosum. Utidelone acts as a microtubule stabilizer and mitotic inhibitor by binding to tubulin at a site distinct from taxanes (such as paclitaxel), leading to G2/M cell cycle arrest and apoptosis via activation of caspase-3 and PARP. It has demonstrated efficacy in overcoming resistance to taxane chemotherapy and can cross the blood-brain barrier. Utidelone was developed primarily for metastatic or recurrent breast cancer patients who have previously received anthracycline or taxane-based regimens. The drug was first approved in China in 2021 for use (in combination with capecitabine) for advanced breast cancer[1][4][5][6][7].

Brand names

优替帝

Other names

优替德隆epothilone Ddesoxyepothilone B